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Abstract
This chapter sheds light on hepcidin, historical view of hepcidin, and the time 
of its discovery in the first section. Then this chapter gives information about the 
genetic aspect and the importance of gene knowledge of hepcidin in explaining 
many disorders in human beings, supported by illustration figures. The regula-
tion of iron in the human body as an essential function of hepcidin is discussed in 
this chapter. Examples of the genes of hepcidin (HAMP and HFE) are highlighted 
in detail as they are essential in regulating iron as well as discussing the genetic 
mutations that occur in these genes and their medical and clinical impacts for many 
diseases such as thalassemia. Finally, the inherited disorders related to hepcidin that 
lead to genetic diseases are discussed.
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1. Introduction
Hepcidin is presently regarded as the key to the iron balance regulator. The 
balance of intracellular iron is preserved by proteins that regulate iron. Hepcidin, 
encoded by the HAMP gene is a 25 amino acid peptide that has been lately found 
[1]. Several mutations in the HAMP gene have been reported. The G71D mutation is 
probable to be linked to reduced hepcidin activity [2]. Mutations in iron-regulating 
proteins cause the disorder (HFE, TfR2, and HAMP) genes. Fekri et al. showed 
that H63D mutation of the HFE gene could play some role in disease evolution. 
In iron homeostasis, the HFE gene plays a very significant role by regulating iron 
absorption [3]. HFE mutations are currently referred to as the reason for decreased 
absorption of iron, iron overload, and hereditary hemochromatosis [4]. Many types 
of research have shown that patients with HFE mutations in beta-thalassemia are 
likely to create hemochromatosis that will require early chelation of iron even in 
heterozygous conditions [5]. Among the mutations discovered most frequently are 
the three missense mutations (SNPs), which are found in the HFE gene. The most 
prevalent mutation within the HFE gene exon 4, leading in a shift of cysteine-to-
tyrosine amino acid at position 282 (C282Y), 60% of hereditary hemochromatosis 
instances in Mediterranean populations accounted for this mutation. H63D is also 
a mutation leading to the replacement of histidine with aspartic acid during a C-G 
shift at nucleotide 187 of exon 2 of the HFE gene. In combination with the C282Y 
allele (C282Y/H63D), hemochromatosis is most pronounced. The HFE gene’s third 
mutation is a substitute for 193AT in exon a pair of with an ensuing serine to cyste-
ine replacement in amino acid position 65 (S65C) [6]. The interaction concerning 
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the mutations over genes influencing blood homeostasis including thalassemia may 
want to hold a synergistic result, increasing the iron storage [7].
2. Hepcidin
2.1 Discovery of hepcidin
The hepcidin molecule (“hep” hepatic origin, “cidin” antimicrobial activity) was 
described in the year 2000; it is an antimicrobial peptide that acts in parts in innate 
immunity and iron metabolism [8]. It is a peptide hormone the liver produces, and 
it works as a regulator of iron [9]. Hepcidin is a regulator of iron homeostasis. Its 
production is increased by iron excess and inflammation and decreased by hypoxia 
and anemia. Hepcidin inhibits the flow of iron into the plasma from duodenal 
enterocytes that absorb dietary iron, macrophages that recycle iron from senescent 
erythrocytes, and iron-storing hepatocytes. Iron-loading anemias are diseases in 
which hepcidin is controlled by ineffective erythropoiesis and concurrent iron 
overload impacts [10]. Hepcidin was isolated from the human urine and blood, 
especially from plasma after filtration [8]. Hepcidin was produced by macrophages, 
adipocytes, neutrophils, lymphocytes, renal cells, and β-cells [11].
Hepcidin is produced by macrophages, adipocytes, neutrophils, lymphocytes, 
renal cells, and β-cells [11]. In the studies of experiment on mice used for the deter-
mination of hepcidin regulation, the expression, function, and structure showed 
that severe iron overload is occurring due to the gene responsible for hepcidin pro-
duction, and the gene has the role of iron regulation. Hepcidin has several functions 
such as inflammation, hypoxia, hypoxia, and iron stores [12]. Hepcidin reacts with 
ferroportin, and the ferroportin is found in spleen, duodenum, and placenta. If the 
ferroportin decreases, it results in reduced iron intake and macrophage release of 
iron and using of the iron, which is stored in the liver [13].
2.2  The hepcidin antimicrobial peptide (HAMP) gene and the structure of 
hepcidin
Hepcidin was initially identified as a liver-expressed antimicrobial peptide 
(LEAP1) with direct antimicrobial activity against a number of bacterial and fungal 
species [14]. It was soon discovered that hepcidin plays a major role in the regula-
tion of iron homeostasis, being overexpressed in the liver with an induced (dietary 
or parenteral) iron overload [15]. Hepcidin acts as a negative regulator of iron 
stores; in response to increased iron levels, the liver increases hepcidin synthesis 
which then acts on the sites of absorption (enterocytes of the duodenum), storage 
(primarily hepatocytes of the liver), or recycling (macrophages of the reticulo-
endothelial system) leading to a decrease in the release of iron from these tissues. 
Hepcidin exerts its influence by binding to and inducing the internalization and 
degradation of ferroportin (FPN), the only known exporter of iron [16].
Gene of human hepcidin is carried out by chromosome 19q13.1. It consists of a 
(2637) nucleated base [17]. HAMP gene was founded in the liver cells in the brain, 
trachea, heart, tonsils, and lung [18]. HAMP gene encodes preprohepcidin, which 
consists of (84) amino acids; hepcidin has three forms: 25 aa, 22 aa, and 20 aa pep-
tides. All the types are founded in urine, while 25 and 20 are founded in human serum 
[19]. Figure 1 shows the structure of hepcidin-25, which consists of (8) cysteine 
linked by disulfide link [21]. Nuclear magnetic resonance spectroscopy (NMR) is 
used for the analysis of the structure of hepcidin; it has four disulfide bonds [22].
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2.3 Iron regulation by hepcidin
The iron content in biological fluids is strictly regulated in all organisms to 
provide iron as required and to prevent toxicity, as excess iron can contribute to 
reactive oxygen species production. Iron homeostasis in mammals is controlled at 
the level of intestinal absorption, as iron is not excreted. Hepcidin, a circulating 
peptide hormone, is the master systemic iron homeostasis regulator that combines 
iron use and processing with the iron acquisition [22].
This hormone is released primarily by hepatocytes and is a negative regulator of 
plasma iron entry (Figure 2).
Figure 1. 
Molecule structure of human synthetic hepcidin-25. Front: an overview of the structure of hepcidin-25. 
Distorted β-sheets are shown as gray arrows, and the peptide backbone is colored gray. The disulfide bonds are 
colored yellow, highlighting the position of an unusual vicinal bond between adjacent cysteines at the hairpin 
turn. Positive residues of arginine (Arg) and lysine (Lys) are pictured in blue, the negative residue of aspartic 
acid (asp) in red, and the histidine containing amino-terminal Cu2 ± Ni2 + (ATCUN)-binding motif in the N 
terminal region is colored green. Background: Hepcidin-25 molecule displayed with a solvent-accessible surface 
that illustrates the amphipathic structure of the molecule [20].
Figure 2. 
Hepcidin internalization and degradation [22].
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Hepcidin works by binding to ferroportin, an iron carrier present in intestinal 
duodenum cells, macrophages, and placenta cells. Hepcidin binding leads to the inter-
nalization and degradation of the ferroportin [16]. Cell surface ferroportin deficiency 
prevents iron from entering the plasma. Reduced iron entry into plasma results in low 
transferrin saturation, and less iron is delivered to the production of erythroblast [23]. 
In addition, reduced hepcidin expression results in increased ferroportin cell surface 
and increased iron absorption. Hepcidin dysregulation leads to iron disorders [24].
Overexpression of hepcidin results in chronic disease anemia, whereas low 
production of hepcidin results in hereditary hemochromatosis with consequent 
accumulation of iron in vital organs [25] (Figure 2). Most inherited iron disorders 
arise from inadequate development of hepcidin relative to the degree of accumula-
tion of tissue iron. Impaired hepcidin expression was found to result from muta-
tions in any of four genes: transferrin receptor 2 (TFR2), hemochromatosis (HFE), 
type 2 hemochromatosis (HFE2), and antimicrobial hepcidin peptide (HAMP) 
[26]. Mutations in HAMP, the gene encoding hepcidin, lead to iron overload disease 
because the absence of hepcidin allows for constitutively high absorption of iron.
Hepcidin-mediated iron homeostasis regulation. As in condition with high levels 
of hepcidin in the bloodstream result in the iron exporter ferroportin which is being 
internalized and degraded. Loss of ferroportin cell surface results in the loading of 
macrophage iron, low levels of plasma iron, and decreased erythropoiesis due to 
decreased iron-bound transferrin. Decreased erythropoiesis causes chronic disease 
anemia and regulates the level of iron imports into plasma, normal transferrin satu-
ration, and normal levels of erythropoiesis in response to iron demand (Figure 3). 
Hemochromatosis, or iron overload, results from the insufficient levels of hepcidin, 
resulting in increased plasma iron imports, high transferrin saturation, and excess 
liver iron deposition [28].
2.4 The HAMP gene mutation
Mutation in the HAMP gene will produce a change in the hepcidin function. 
HAMP gene consists of exon 3, the last exon is encoded proteins, and it is consid-
ered the most important and largest area in the gene and is contained on many 
polymorphisms [29]. Polymorphisms are in the HFE gene more than in the HAMP 
gene. There are about 16 types of single nucleotide polymorphism founded in differ-
ent studies [30]. Many reports detected (8) mutations in the gene. The persons who 
Figure 3. 
Regulation of iron balance [27].
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carry mutations in the HAMP gene show juvenile hemochromatosis, which occurs 
at 10–30 years [31]. The microsatellite marker probes are used as the first genetic 
alteration in the HAMP gene [32]. In some time, the mutation occurs in c.233G > A 
after exchanging of some amino acids’ inactive peptide or substitution of C78 by a 
tyrosine, C78T. The mutation makes possible the bisulfite bonds binding of ferro-
portin to hepcidin, which results in the accumulation absorbed of iron [33].
Mutation of C70R causes malformation in the bisulfite bond of the cysteines. 
The arginine becomes an alternative for the cysteine that its exchanging does not 
allow the production of bisulfite bridge between (3) and (6) in hepcidin peptide 
[34]. Alteration of C to T was occurring at position (166) (166C-T) of the HAMP 
gene and alteration of arginine at position (56) for a stopping codon (R56X), 193A 
to (T). As well as the ferroportin also does not bind to hepcidin, producing more 
iron. While defect in guanine exon 2 at position 93 leads to a mutation in RNA [35], 
defect in Met50del from exon 2 causes a disorder in the expression of the active 
peptide and causes changes in reading frames. Another mutation, G71D, alters to 
amino acid 71, which is between (3–4) cysteine, which prevents linking with fer-
roportin [36].
HFE-H63D variant is associated with the HAMP-G71D variant in sickle cell 
disease patients and increases iron overload [37]. The polymorphism (G to A) at the 
+14 position of the 5′-UTR regions produce new initiation codon, inducing yielding 
of a new abnormal protein and change in the reading frame. Unstable protein will 
be generated, which is analyzed after the translation of the mRNA [38]. The haplo-
type of the HAMP gene is caused by the linked of polymorphisms NC-582A > G and 
NC-1010C > T, with ferritin concentration more than 300 μg/L [39].
The association of HFE gene polymorphisms and HAMP is common. In some 
clinical cases, there are several mixed clinical signs, with iron overload. The variants 
C-582A > G and C-153C > T decrease hepcidin expression, but the mechanism of 
action of peptide stays the same without transferrin saturation and increasing fer-
ritin [40]. The body organs contain iron at large amounts such as the heart and liver, 
and it will be affected and damaged [41]. Any change in the HAMP gene may cause 
a defective hepcidin protein, and it became no action. Accumulation of iron and 
ferritin in the organs helps to develop diseases in different organs such as coronary 
diseases, diabetes mellitus, HIV, HBV, and HCV [42]. It was noticed that some 
neurodegenerative diseases are associated with a high level of hepcidin in plasma 
such as Alzheimer, Parkinson, and sclerosis [43].
2.5 Homeostatic iron regulation gene (HFE) human
Human homeostatic iron regulator protein, also known as the HFE protein 
(HighmFE2+), is a protein that in humans is encoded by the HFE gene. The HFE 
gene is located on the short arm of chromosome 6 at location 6p21.3 [44]. Simon 
and colleagues, in the 1970s, noted that hemochromatosis is relatively common, 
associated with markers of human leukocyte antigen (HLA), and transmitted as 
an autosomal recessive trait [45]. In 1996, Feder and colleagues used positional 
cloning to classify HFE, the gene of hemochromatosis, associated with the main 
chromosome 6p histocompatibility complex (MHC) [46]. The HFE membrane 
protein is similar to the proteins of the MHC class I and binds beta-2 microglobulin 
(β2M) [46]. HFE binds the extracellular α1-α2 domain to the transferrin receptor 
(TFRC) [47]. HFE is needed for normal hepatic synthesis regulation of hepcidin, 
the principal iron metabolism controller [25].
Common HFE mutations represent approximately 90% of phenotypes of 
hemochromatosis in Western European descent whites. Feder and colleagues named 
the gene HLA-H [46] although the name had been published earlier to designate 
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a presumed pseudogene in the HLA class I region [48]. Marsh demanded a more 
suitable designation [49]. The HFE symbol (H = high; FE = iron) was accepted by 
both the WHO Nomenclature Committee for HLA System Factors and the HUGO 
Genome Nomenclature Committee.
2.6 Structure and function of HFE gene human
HFE has seven exons of 12 kb [39]. HFE includes 9.6 kb of DNA on chromosome 6p 
in the extended region of HLA class I. Histone genes on both sides of HFE are present 
[50]. Exon 1 corresponds to the peptide of the signal and exons 2–4, respectively, to the 
domains α1, α2, and α3. For the transmembrane domain, exon 5 accounts. The cyto-
plasmic tail is encoded by exon 6’s 5′ portion, which includes a native stop codon. The 
full-length transcript, therefore, represents six exons [51]. HFE is a protein contain-
ing 343 amino acids, including a signal peptide, an extracellular transferrin-binding 
region (α1 and α2), an immunoglobulin-like domain (α3), a transmembrane region, 
and a short cytoplasmic tail. HFE binds β2 M to form a cell surface heterodimer [46].
HFE is glycosylated at asparagine residues 110, 130, and 234 during transport to 
the cell membrane. For normal intracellular trafficking and function, glycosylation 
is important. HFE interacts with TFRC [51, 52]. HFE’s structure revealed that its 
TFRC ligand binds in a molar ratio of 2:1 TFRC: HFE [47]. There is a peptide-binding 
groove in most class I MHC molecules. Since the α1 and α2 helices are closer to 
HFE, the HFE analog site is too narrow to bind peptides [47]. TFRC and HFE bind 
strongly to the essential pH of cell surfaces but not to the intracellular vesicle acid 
pH [47]. The structure of a complex between the extracellular portions of HFE and 
TFRC shows that binding affects both HFE and its ligand configurations. In their 
domain arrangements and dimer interfaces, the structures of TFRC alone and TFRC 
complexed with HFE differ [53].
Studies of 293 cells cultivated to express wild-type HFE proteins showed that 
with TFR, HFE forms stable complexes. The association of HFE protein with TFR 
was significantly reduced in 293 cells over the expression of HFE C282Y, as shown 
in Figure 4 [54]. Through inhibiting TFRC: TF-Fe interaction in an experiment 
using purified proteins and a biosensor chip [47], normal HFE protein decreased 
the affinity of TFRC to TF. HFE changes the conformation of the Tf-Fe binding site 
as observed by biosensor assays when HFE binds to TFRC in vitro, decreasing the 
entry of iron into Chinese ovarian hamster cells [47]. No evidence of binding of 
HFE and TFR2 was detected in coimmunoprecipitation or surface resonance-based 
testing experiments using soluble HFE and TFR2 [55].
Figure 4. 
The HFE gene diagram. The image was changed after getting permission from the author. Cys282 -> Tyr282 
exchanging mutation of C282Y and His63 -> Asp63 exchanging mutation of H63D [54].
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The relevance, if any, of these in vitro results to in vivo iron homeostasis is 
unclear. Many factors, including HFE, act as hepcidin transcription upstream regu-
lators [18]. HAMP expression in untreated patients with hemochromatosis, homo-
zygosity of C282Y, and iron overload was significantly lower than controls [56].
2.7 Mutation of the HFE gene
The three most common mutations of HFE in the coding region are: C282Y 
(exon 4; c.845GA; rs1800562), H63D (exon 2; c.187CG; rs1799945), and S65C 
(exon 2; c.193AT; rs1800730) [57]. The C282Y mutation interrupts a critical 
disulfide bond in HFE’s α3 domain, abrogating its binding to β2 M and limiting 
its location to the cytoplasm [58]. H63D and S65C affect the α1 binding groove 
but do not prevent HFE on cell surfaces. HFE C282 is conserved because cysteine 
282 is essential to β2M binding and extracellular presentation of HFE. H63 is also 
conserved. Histidine 63 forms a salt bridge in the α2 domain that binds TFRC, 
 suggesting that the salt bridge is important for HFE function [59].
Histidine 116 and 145 and tyrosine 140 are widely conserved. A cluster of four 
histidine residues (H109, H111, H116, and H145) is associated with Y140 in the α1 
domain. This configuration resembles functional sites in other iron-binding proteins 
[40]. Hereditary hemochromatosis type-1 is caused by HFE gene mutation. Allelic is 
most prevalent among the individuals of Europe [60]. Single point simple change in 
exon 4, 845G to 845A in the HFE gene results in an exchange of cysteine by tyrosine. 
Also, another gene mutation included a change of the allele 187C to 187G, wherever 
histidine is exchanged. The substitution of serine for cysteine is considered the 
third mutation of the HFE gene S65C [61]. Also, H63D mutation is present in HFE 
protein, causing a decrease in the transferrin receptor [62]. When hepcidin protein 
cannot bind with the transferrin receptor, another factor has a great role in hep-
cidin protein, therefore, any changes in hepcidin protein help to aggregation iron 
by inhibiting the transcription of hepcidin and do not allow iron absorption from 
the intestine [63]. Also, the modifying of the H63D genotype associated between 
the metabolism of iron and lead, wherever there is increased iron in the body, is 
associated with a high level in the same body [64]. Iron overload has been identified 
in individuals with the digenic inheritance of one or more HFE mutations and a 
non-HFE gene mutation that is also involved in iron metabolism [44]. One example 
is the development of hemochromatosis in individuals who are double heterozygous 
for one or more HFE mutations and a hepcidin gene mutation (HAMP) [65].
Iron loading occurred in people with HFE mutation digenic inheritance and either 
a hemojuvelin gene (HJV) mutation [58] or a TFR2 gene (TFR2) mutation [66].
2.8 Iron overload and genetic alterations
Activation of the HFE gene works with hemochromatosis that includes iron 
accumulation that occurs with heart failure, cirrhosis, diabetes, and hepato-
carcinoma. Interaction between β2-microglobulin and HFE protein is the main 
hypothesis that explains the development of hemochromatosis in the body. 
β2-microglobulin and HFE protein react together and form the transferrin-1 
receptor, which helps to absorbed iron from the diet [67]. Many reports founded 
new genes responsible for the iron metabolism [hereditary hemochromatosis 
(HH)]. It included two types, the first type is HFE hemochromatosis that occurs 
due to mutation of the HFE gene, and its spread commonly in the Caucasian peo-
ple. The second type is non-HFE hemochromatosis. Non-HFE hemochromatosis, 
including HAMP, ferroportin, TFR, and HJV gene, is detected among the diseases. 
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with the occurrence of hyperferritinemia [44, 68]. The accumulation of iron in the 
tissues interferes with tissues’ function, such as hepatic failure, cardiac problems, 
cirrhosis, and diabetes. Furthermore, there are pituitary gland diseases and disor-
der in the function of joints, gonads, abdominal pain, and hyperpigmentation of 
the skin [69].
Hemochromatosis diagnosis is made by deepening on clinical signs, biochemical 
markers, genetic examination, and Liver biopsy [70]. Some indicators, such as fer-
ritin, transferrin iron elevated, and liver enzymes, are elevated in hemochromatosis 
patients. The level of ferritin in serum is greater 300 μg/L in men and 200 μg/L in 
women, also the same speech on the level of transferrin. If the level of ferritin and 
transferring are elevated, it should make a genetic analysis of some genes such as 
HAMP, HJV, HFE, transferrin receptor genes, and ferroportin [71].
3. Conclusions
The knowledge about hepcidin and its genetic structure, as well as a common 
mutation that occurs in it, is vital to understand the iron metabolism and iron 
disorders. This chapter helps the reader to get ideas about that.
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